Recently approved NMDA blocker for the management of treatment resistant depression in adults is?
Correct Answer: ESKETAMINE
Description: ESKETAMINE: a. Non - Competitive NMDA receptor antagonist b. Used for treatment of Resistant Depression in Adults c. Supplied as a spray for intranasal administration d. Comes with a BLACK BOX WARNING: 1. Risk for sedation and dissociation after administration 2. Potential for abuse and misuse 3. Increased risk of suicidal thoughts and behaviors in pediatrics and young adult patients taking antidepressants SIPONIMOD: a. Used for treatment for relapsing form of Multiple Sclerosis (MS). b. Oral administration c. Sphingosine -1- phosphate (S1P) receptor Modulator like FINGOLIMOD d. SIPONIMOD blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in Peripheral blood. ERDAFITINIB: a. Tyrosine kinase inhibitor b. Used for bladder cancer RISANKIZUMAB: a. Mab against IL-23 b. Used in Plaque Psoriasis
Category:
Pharmacology
Get More
Subject Mock Tests
Practice with over 200,000 questions from various medical subjects and improve your knowledge.
Attempt a mock test nowMock Exam
Take an exam with 100 random questions selected from all subjects to test your knowledge.
Coming SoonGet More
Subject Mock Tests
Try practicing mock tests with over 200,000 questions from various medical subjects.
Attempt a mock test now